| Characteristic . | ARIS group (n = 19) . | AT/IMT group (n = 20) . | AT/RT group (n = 17) . | AT group (n = 18) . |
|---|---|---|---|---|
| Age (years) | 63.9 (59.8–68) | 68.1 (65.2–71) | 67.5 (64–70.9) | 64.8 (60.4–69.1) |
| Males/females | 17/2 | 20/0 | 16/1 | 16/2 |
| BMI (kg/m2) | 28.6 (26.7–30.4) | 29 (27.4–30.7) | 28.6 (26.8–30.3) | 26.9 (25.4–28.5) |
| NYHA class, n (%) | ||||
| II | 9 (47) | 11 (55) | 10 (59) | 11 (61) |
| III | 10 (53) | 9 (45) | 7 (41) | 7 (39) |
| Disease aetiology, n (%) | ||||
| DCM | 6 (32) | 8 (40) | 5 (29) | 8 (44) |
| ICM | 13 (68) | 12 (60) | 12 (71) | 10 (66) |
| LVEF (%) | 28.3 (25.9–30.7) | 28.8 (25.1–32.5) | 29.6 (27.2–32.1) | 26.8 (24.7–28.8) |
| peakVO2 (mL/kg/min) | 17.4 (15.2–19.5) | 16.6 (15–18.3) | 17. 4 (15.6–19.3) | 18 (15.9–20) |
| PImax (cmH2O) | 82.6 (73.9–91.3) | 85.6 (75.6–95.5) | 79.8 (70.3–89.4) | 83.1 (75.3–90.8) |
| QMS (kg) | 23.5 (20.2–26.7) | 21.3 (18.5–24.1) | 23.2 (19.6–26.8) | 22.1 (18.7–25.5) |
| Medication, n (%) | ||||
| ACE inhibitors | 18 (95) | 20 (100) | 15 (88) | 18 (100) |
| Beta-blockers | 16 (84) | 20 (100) | 15 (88) | 16 (89) |
| Antiarrhythmic drugs | 4 (21) | 5 (25) | 4 (24) | 3 (17) |
| Diuretics | 17 (89) | 20 (100) | 16 (94) | 18 (100) |
| MRA | 12 (63) | 15 (75) | 12 (71) | 13 (72) |
| ARB | 1 (5) | 1 (5) | 0 (0) | 2 (11) |
| Characteristic . | ARIS group (n = 19) . | AT/IMT group (n = 20) . | AT/RT group (n = 17) . | AT group (n = 18) . |
|---|---|---|---|---|
| Age (years) | 63.9 (59.8–68) | 68.1 (65.2–71) | 67.5 (64–70.9) | 64.8 (60.4–69.1) |
| Males/females | 17/2 | 20/0 | 16/1 | 16/2 |
| BMI (kg/m2) | 28.6 (26.7–30.4) | 29 (27.4–30.7) | 28.6 (26.8–30.3) | 26.9 (25.4–28.5) |
| NYHA class, n (%) | ||||
| II | 9 (47) | 11 (55) | 10 (59) | 11 (61) |
| III | 10 (53) | 9 (45) | 7 (41) | 7 (39) |
| Disease aetiology, n (%) | ||||
| DCM | 6 (32) | 8 (40) | 5 (29) | 8 (44) |
| ICM | 13 (68) | 12 (60) | 12 (71) | 10 (66) |
| LVEF (%) | 28.3 (25.9–30.7) | 28.8 (25.1–32.5) | 29.6 (27.2–32.1) | 26.8 (24.7–28.8) |
| peakVO2 (mL/kg/min) | 17.4 (15.2–19.5) | 16.6 (15–18.3) | 17. 4 (15.6–19.3) | 18 (15.9–20) |
| PImax (cmH2O) | 82.6 (73.9–91.3) | 85.6 (75.6–95.5) | 79.8 (70.3–89.4) | 83.1 (75.3–90.8) |
| QMS (kg) | 23.5 (20.2–26.7) | 21.3 (18.5–24.1) | 23.2 (19.6–26.8) | 22.1 (18.7–25.5) |
| Medication, n (%) | ||||
| ACE inhibitors | 18 (95) | 20 (100) | 15 (88) | 18 (100) |
| Beta-blockers | 16 (84) | 20 (100) | 15 (88) | 16 (89) |
| Antiarrhythmic drugs | 4 (21) | 5 (25) | 4 (24) | 3 (17) |
| Diuretics | 17 (89) | 20 (100) | 16 (94) | 18 (100) |
| MRA | 12 (63) | 15 (75) | 12 (71) | 13 (72) |
| ARB | 1 (5) | 1 (5) | 0 (0) | 2 (11) |
No significant differences (P = ns) were found between baseline characteristics in study groups.
ARB, angiotensin II receptor blockers; BMI, body mass index; DCM, dilated cardiomyopathy; ICM, ischaemic cardiomyopathy; LVEF, left ventricular ejection fraction; MRA, mineral corticoid receptor antagonist; NYHA, New York Heart Association; peak VO2, peak oxygen consumption; PImax, maximal inspiratory pressure; QMS, quadriceps muscle strength.
| Characteristic . | ARIS group (n = 19) . | AT/IMT group (n = 20) . | AT/RT group (n = 17) . | AT group (n = 18) . |
|---|---|---|---|---|
| Age (years) | 63.9 (59.8–68) | 68.1 (65.2–71) | 67.5 (64–70.9) | 64.8 (60.4–69.1) |
| Males/females | 17/2 | 20/0 | 16/1 | 16/2 |
| BMI (kg/m2) | 28.6 (26.7–30.4) | 29 (27.4–30.7) | 28.6 (26.8–30.3) | 26.9 (25.4–28.5) |
| NYHA class, n (%) | ||||
| II | 9 (47) | 11 (55) | 10 (59) | 11 (61) |
| III | 10 (53) | 9 (45) | 7 (41) | 7 (39) |
| Disease aetiology, n (%) | ||||
| DCM | 6 (32) | 8 (40) | 5 (29) | 8 (44) |
| ICM | 13 (68) | 12 (60) | 12 (71) | 10 (66) |
| LVEF (%) | 28.3 (25.9–30.7) | 28.8 (25.1–32.5) | 29.6 (27.2–32.1) | 26.8 (24.7–28.8) |
| peakVO2 (mL/kg/min) | 17.4 (15.2–19.5) | 16.6 (15–18.3) | 17. 4 (15.6–19.3) | 18 (15.9–20) |
| PImax (cmH2O) | 82.6 (73.9–91.3) | 85.6 (75.6–95.5) | 79.8 (70.3–89.4) | 83.1 (75.3–90.8) |
| QMS (kg) | 23.5 (20.2–26.7) | 21.3 (18.5–24.1) | 23.2 (19.6–26.8) | 22.1 (18.7–25.5) |
| Medication, n (%) | ||||
| ACE inhibitors | 18 (95) | 20 (100) | 15 (88) | 18 (100) |
| Beta-blockers | 16 (84) | 20 (100) | 15 (88) | 16 (89) |
| Antiarrhythmic drugs | 4 (21) | 5 (25) | 4 (24) | 3 (17) |
| Diuretics | 17 (89) | 20 (100) | 16 (94) | 18 (100) |
| MRA | 12 (63) | 15 (75) | 12 (71) | 13 (72) |
| ARB | 1 (5) | 1 (5) | 0 (0) | 2 (11) |
| Characteristic . | ARIS group (n = 19) . | AT/IMT group (n = 20) . | AT/RT group (n = 17) . | AT group (n = 18) . |
|---|---|---|---|---|
| Age (years) | 63.9 (59.8–68) | 68.1 (65.2–71) | 67.5 (64–70.9) | 64.8 (60.4–69.1) |
| Males/females | 17/2 | 20/0 | 16/1 | 16/2 |
| BMI (kg/m2) | 28.6 (26.7–30.4) | 29 (27.4–30.7) | 28.6 (26.8–30.3) | 26.9 (25.4–28.5) |
| NYHA class, n (%) | ||||
| II | 9 (47) | 11 (55) | 10 (59) | 11 (61) |
| III | 10 (53) | 9 (45) | 7 (41) | 7 (39) |
| Disease aetiology, n (%) | ||||
| DCM | 6 (32) | 8 (40) | 5 (29) | 8 (44) |
| ICM | 13 (68) | 12 (60) | 12 (71) | 10 (66) |
| LVEF (%) | 28.3 (25.9–30.7) | 28.8 (25.1–32.5) | 29.6 (27.2–32.1) | 26.8 (24.7–28.8) |
| peakVO2 (mL/kg/min) | 17.4 (15.2–19.5) | 16.6 (15–18.3) | 17. 4 (15.6–19.3) | 18 (15.9–20) |
| PImax (cmH2O) | 82.6 (73.9–91.3) | 85.6 (75.6–95.5) | 79.8 (70.3–89.4) | 83.1 (75.3–90.8) |
| QMS (kg) | 23.5 (20.2–26.7) | 21.3 (18.5–24.1) | 23.2 (19.6–26.8) | 22.1 (18.7–25.5) |
| Medication, n (%) | ||||
| ACE inhibitors | 18 (95) | 20 (100) | 15 (88) | 18 (100) |
| Beta-blockers | 16 (84) | 20 (100) | 15 (88) | 16 (89) |
| Antiarrhythmic drugs | 4 (21) | 5 (25) | 4 (24) | 3 (17) |
| Diuretics | 17 (89) | 20 (100) | 16 (94) | 18 (100) |
| MRA | 12 (63) | 15 (75) | 12 (71) | 13 (72) |
| ARB | 1 (5) | 1 (5) | 0 (0) | 2 (11) |
No significant differences (P = ns) were found between baseline characteristics in study groups.
ARB, angiotensin II receptor blockers; BMI, body mass index; DCM, dilated cardiomyopathy; ICM, ischaemic cardiomyopathy; LVEF, left ventricular ejection fraction; MRA, mineral corticoid receptor antagonist; NYHA, New York Heart Association; peak VO2, peak oxygen consumption; PImax, maximal inspiratory pressure; QMS, quadriceps muscle strength.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
